During the scan, a short‑acting medicine is given through an IV to make the heart work a little harder, allowing doctors to see how the blood vessels respond. The medicines used are Adenosine and regadenoson, both of which safely cause a temporary rise in heart workload. A small amount of a harmless radioactive substance, O15-water, is also injected so the scanner can create detailed pictures of blood flow. The amount of blood moving through the heart muscle is expressed as MBF, which helps identify areas that may not be getting enough oxygen.

The purpose of the study is to find specific numbers that can predict the chance of future major heart problems, known as MACE. Participants undergo the PET scan with the stress medicines, then are followed for several years while information about any heart attacks, deaths, or related events is recorded. This follow‑up helps determine which scan results are linked to higher or lower risk.

To monitor the effects of the treatment, PET/CT scans, which are specialized imaging tests that show how the body uses certain substances, will be used to look at the state of the arteries. These scans help track changes in inflammation levels within the carotid arteries, which are the main blood vessels located in the neck. The process involves comparing the level of inflammation at the beginning of the study to the level measured after six months of treatment.

The purpose of this study is to determine if EA-230 can reduce the amount of time a patient needs to stay in the hospital after surgery. Participants will receive either EA-230, which is given as a solution for infusion through an intravenous line, or a placebo. This is a randomized trial, meaning participants are assigned to a group by chance, and it is double-blind, meaning neither the patients nor the medical staff know which substance is being administered.

The purpose of the study is to find out how many patients with coronary artery disease and prediabetes can return to normal blood sugar levels when treated with these blood sugar-lowering medications. The study will also look at whether patients with prediabetes have more problems with their eyes, kidneys, nerves, and liver compared to patients with normal blood sugar levels. During the study, patients will receive treatment for one year, and then they will be followed for another year to see if their blood sugar levels stay normal or if prediabetes comes back, or if they develop diabetes.

The study will measure blood sugar control using a blood test called HbA1c, which shows the average blood sugar level over the past few months. Other measurements will include kidney function tests, liver health markers, cholesterol levels, body weight, and waist size. The study will also check for complications that can affect the eyes, kidneys, and nerves, as well as a liver condition called MASLD, which is a buildup of fat in the liver. The study will compare patients who receive the blood sugar-lowering medications with those who receive standard care to see which approach is more effective in bringing blood sugar levels back to normal and preventing diabetes.

The purpose of the study is to find out whether lidocaine given through a vein can lower the levels of a substance called interleukin-6 in the blood six hours after surgery ends. Interleukin-6 is a marker of inflammation in the body, and high levels of it are associated with the inflammatory response caused by the heart-lung machine. The study will also measure other markers of inflammation and heart stress, including C-reactive protein, high-sensitivity Troponin T, and TNF-α, at different times before, during, and after surgery. Additionally, the study will look at whether patients who receive lidocaine have fewer complications after surgery, spend less time in the intensive care unit, have better survival rates one month after surgery, and experience less pain in the days following the operation.

Patients in the study will be randomly assigned to receive either lidocaine or placebo during their surgery and for a period afterward. Neither the patients nor the doctors will know which treatment is being given, which helps ensure fair and accurate results. Blood samples will be taken at specific times to measure the inflammation markers, and information about any complications, length of stay in the intensive care unit, heart rhythm problems after the heart is restarted, pain levels, and need for pain medication will be collected. The study is expected to begin enrolling patients in October 2025 and continue until April 2027.

The purpose of the study is to find out if XC001 can reduce the amount of heart muscle that does not receive enough blood after bypass surgery, and to assess whether it can improve how well the heart contracts and pumps blood. The study will use a special type of imaging called cardiovascular magnetic resonance imaging, which creates detailed pictures of the heart while it is under stress to show areas that are not getting enough blood flow. The study is designed to last 26 weeks, with an additional 26-week extension period for those who continue. Patients will be randomly assigned to receive either XC001 or placebo during their bypass surgery, and neither the patients nor the doctors will know which treatment is given until the study is completed.

After the bypass surgery, patients will undergo imaging tests at several time points to measure changes in blood flow to the heart and how well the heart is functioning. The first imaging will be done a few days after surgery to establish a starting point, and then additional imaging will be performed at 12 weeks and 26 weeks after surgery. For those who participate in the extension period, another imaging test will be done at 52 weeks. Throughout the study, doctors will monitor the safety of the treatment and track any side effects or complications that may occur. The study will compare the results between patients who received XC001 and those who received placebo to determine if the gene therapy provides any benefit in improving blood flow to areas of the heart that could not be fully treated by bypass surgery alone.

The study will use two different antibiotics: ceftriaxone, which is given through an intravenous infusion (through a vein), and amoxicillin, which is taken as tablets by mouth. These medications will target specific bacteria that have been found in the fatty deposits that build up in the arteries of patients with heart attacks.

During the study, patients will receive antibiotic treatment for up to two weeks. The medications will be used to target bacteria that are commonly found in complicated artery blockages. Patients will be monitored for heart-related events and complications over several years after receiving the treatment.

The study examines three different treatment combinations: acetylsalicylic acid (also known as aspirin) at a low dose (75 mg) plus prasugrel (10 mg), aspirin alone at a high dose (300 mg), or aspirin alone at a low dose (75 mg). These medications help prevent blood clots from forming in the newly created bypass grafts. The treatment period with these specific combinations lasts for three months, after which all patients continue with low-dose aspirin only.

The research will track how well the bypass grafts remain open over time and monitor for complications such as bleeding, heart attacks, or the need for additional procedures. Patients will be followed for 12 months after their surgery to evaluate the effectiveness and safety of these different medication combinations.

The treatment involves comparing two medications: Xeter (which contains rosuvastatin, a type of statin medication that helps lower cholesterol) and placebo. The study aims to measure changes in the volume and composition of plaques in heart arteries after three months of treatment.

During the study, participants will undergo heart imaging at the beginning of the study and after three months of taking either Xeter or placebo. The medication is taken as a film-coated tablet by mouth. The maximum daily dose of Xeter is 40 milligrams, and treatment continues for up to 12 months. The study will track various aspects of heart health and monitor how the plaques in the arteries may change over time.

The purpose of the study is to see if taking statins can reduce the risk of heart-related problems and death in people with a high genetic risk for heart disease. Participants in the study will be randomly assigned to receive either a statin or a placebo. The study will last for about five years, during which time participants will take the medication daily and have regular check-ups to monitor their health and any side effects.

Throughout the study, researchers will look at how well the statins work in preventing major heart problems, such as heart attacks and strokes. They will also monitor other health factors like cholesterol levels, blood pressure, and overall health. The study aims to provide valuable information on whether using statins based on genetic risk can be an effective way to prevent heart disease.

The purpose of the study is to determine if flecainide is better than amiodarone in helping patients return to a normal heart rhythm. Participants will receive either flecainide or amiodarone through an injection. The study will monitor how well each medication works in restoring normal heart rhythm and how safe they are for the patients. The effects of the medications will be observed for up to 24 hours, with particular attention to any side effects or complications that may arise.

Throughout the study, the frequency of successful heart rhythm conversion and any side effects will be recorded. The trial aims to provide valuable information on the effectiveness and safety of these medications in treating paroxysmal atrial fibrillation in patients with coronary artery disease. This research could help improve treatment options for individuals experiencing this heart condition.

Participants in the study will be randomly assigned to receive either Brilique or Clopidogrel Medreg. The study will last for about 12 months, during which time the safety and effectiveness of the medication will be monitored. This includes checking for any major bleeding events and tracking any occurrences of heart attacks, strokes, or issues with the stent used in PCI. The study will also use a health questionnaire to assess the overall well-being of participants.

The study aims to provide valuable information on whether genetic testing can help tailor the choice of medication for patients undergoing PCI, potentially improving outcomes and reducing risks. This approach could lead to more personalized treatment plans for individuals with coronary artery disease who are also on DOACs.

The purpose of the study is to evaluate how the flu vaccine affects inflammation in the body, specifically looking at a marker called high-sensitivity C-reactive protein (hsCRP). Inflammation is the body’s response to injury or infection, and it can play a role in heart disease. Participants in the study will receive the flu vaccine either immediately or after a one-month delay. The study will measure changes in inflammation levels over this period.

Throughout the study, additional markers related to heart disease risk and immune response will be monitored. These include substances like interleukin-6 and tumor necrosis factor-alpha, as well as the presence of certain immune cells. The study aims to provide insights into how the flu vaccine might influence inflammation and immune function in people with stable coronary artery disease.

Participants in the study will be patients undergoing a type of heart surgery known as CABG (Coronary Artery Bypass Grafting), which is performed to improve blood flow to the heart. The study will last for one month, during which participants will receive either the combination of ticagrelor and aspirin or aspirin alone. The researchers will then monitor the participants for one year to assess the incidence of heart-related events such as heart attacks, strokes, and any issues with the grafts used in the surgery.

The study aims to provide valuable information on whether the combination of ticagrelor and aspirin is more effective than aspirin alone in reducing the risk of heart-related events after CABG surgery. This information could help improve treatment strategies for patients with coronary artery disease undergoing this type of surgery. Participants will be followed up for a total of five years to gather long-term data on their health and quality of life.

The purpose of the study is to evaluate how oxycodone affects breathing after heart surgery. Researchers will monitor patients’ oxygen levels and breathing patterns to understand any changes that occur with the use of oxycodone. The study will also look at how much oxycodone is used and its concentration in the blood. Additionally, the study will assess pain levels, any complications from surgery, and overall quality of life after the surgery.

Participants in the study will receive either oxycodone or a placebo. The study will take place over a period of time, with regular check-ins to monitor the effects of the medication. The goal is to gather information on both the short-term and long-term outcomes of using oxycodone for pain management after heart surgery.

Participants in the study will receive either the ziltivekimab treatment or a placebo for a period of 20 weeks. During this time, researchers will use advanced imaging techniques to look at the arteries and measure changes in inflammation. They will also examine blood samples to study changes in certain cells and proteins that are related to inflammation. The study aims to provide a better understanding of how ziltivekimab affects the body, particularly in reducing inflammation associated with coronary artery disease.

The study will involve regular monitoring and assessments to track the effects of the treatment. By the end of the study, researchers hope to determine whether ziltivekimab is effective in reducing inflammation in patients with coronary artery disease. This information could help in developing new treatments for managing this heart condition in the future.

The purpose of the study is to compare the effectiveness of these medications in slowing down or reversing the buildup of plaque in the arteries of the heart, which is a key factor in coronary artery disease. The study will last for 24 months, during which participants will receive one of the medications along with advice on diet and lifestyle changes. The progress of the disease will be monitored using a special type of X-ray called computed tomography (CT), which provides detailed images of the heart and its blood vessels.

Participants will be randomly assigned to receive either semaglutide, dapagliflozin, metformin, or a placebo. The study aims to observe how these treatments affect the progression of coronary artery disease and other health factors such as weight, blood pressure, and cholesterol levels. The results will help determine which medication is most effective in managing coronary artery disease in patients with prediabetes.

The purpose of this study is to investigate how well rivaroxaban works and how safe it is for patients with atrial fibrillation after they have had PCI. The study will involve 50 patients who will take rivaroxaban for up to 12 months. During this time, researchers will monitor the patients for any health changes, including any potential side effects or complications. The study will also include testing for a specific genetic marker called CYP2C19 genotype, which may affect how patients respond to the medication.

Throughout the study, researchers will keep track of important health outcomes, such as the occurrence of heart attacks, strokes, or any bleeding events. The study aims to provide valuable information on whether rivaroxaban can be safely used as a single treatment for patients with atrial fibrillation who have undergone PCI. This research is expected to be completed by early 2026, with patient recruitment starting in 2024.

Participants in the study will receive either Propofol or Remifentanil through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will compare the actual levels of these medications in the blood with the levels predicted by the model. This will help determine if the model can accurately predict how the medications work during surgery. The study will also involve a placebo group to compare results.

The trial will last for a short period, focusing on the time during and immediately after the surgery. The researchers will collect data on the concentration of the medications in the blood and compare it to the predictions made by the model. This information will help improve the understanding of how these medications can be used safely and effectively during heart surgeries. The study aims to ensure that the model’s predictions are within an acceptable range, which will help in providing better anesthesia care for patients undergoing these types of surgeries.

The purpose of the study is to compare the effectiveness of a short duration of DAPT, lasting 1 month, with the usual longer duration of 6 to 12 months. The study aims to see how these different durations affect the occurrence of adverse events, such as bleeding or ischemic events, which are problems caused by reduced blood flow, over a period of 12 months. Patients who have successfully undergone a procedure called coronary angioplasty for their blocked artery will be part of this study. This procedure involves using a small balloon to open up the blocked artery.

Participants in the study will be randomly assigned to receive either the short or long duration of DAPT. They will be monitored over the course of a year to track any adverse events, such as bleeding or heart-related issues, and to assess their overall health and quality of life. The study will also evaluate the costs associated with each treatment duration and how well patients adhere to their medication regimen. The goal is to determine which treatment duration is more beneficial for patients in terms of safety and effectiveness.

The main purpose of this research is to evaluate how safe RBD4059 is when given as multiple doses to patients with stable heart disease who are already taking low-dose aspirin. During the study, some participants will receive the actual medication while others will receive a placebo through injections under the skin. The treatment period will last for 12 months.

The study will involve regular check-ups to monitor participants’ health, including blood tests, physical examinations, and heart measurements using ECG (a test that records the heart’s electrical activity). The researchers will also measure how the body processes the medication and how it affects certain blood components related to clotting. Neither the participants nor their doctors will know who is receiving the actual medication or the placebo during the study.

The purpose of the study is to evaluate the safety and effectiveness of this gene therapy in patients with severe coronary artery disease who cannot undergo revascularization procedures. Participants in the study will receive either the gene therapy or a placebo, and neither the participants nor the researchers will know who receives which treatment. The treatment is administered through an injection directly into the heart.

Throughout the study, participants will be monitored to assess improvements in their ability to perform physical activities, such as walking, and any changes in their symptoms. The study aims to determine if the gene therapy can enhance the heart’s blood supply and improve the quality of life for those with refractory angina. The trial is expected to continue until the end of 2027.

Participants in the study will be randomly assigned to receive either inclisiran or a placebo, which is a substance with no active medication. The study will last for 24 months, during which participants will continue their current statin therapy. The progress of the fatty deposits in the heart will be monitored using a special imaging method called coronary computed tomography angiography (CCTA). This method allows doctors to see detailed images of the heart’s arteries and assess any changes in the buildup of fatty deposits over time.

The main goal of the study is to determine if inclisiran is more effective than the placebo in reducing the total volume of fatty deposits in the heart’s arteries. Additionally, the study will look at changes in cholesterol levels and the volume of specific types of fatty deposits. The safety of inclisiran will also be monitored by recording any side effects or serious health events that occur during the study. Participants will be closely observed to ensure their well-being throughout the trial.

Participants in the study will be randomly assigned to receive either Colchicine or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow participants over time to monitor their health and any heart-related events they may experience. The goal is to determine if Colchicine can help improve outcomes for people with coronary artery disease after they have had PCI.

The study will track the time it takes for participants to experience any major heart-related events, such as heart attacks or strokes, and will also assess changes in symptoms like chest pain and shortness of breath. This research is important for understanding how Colchicine might benefit patients with coronary artery disease and potentially improve their quality of life.

The purpose of the study is to evaluate the outcomes of using a reduced antiplatelet therapy after the implantation of an Angiolite stent, a small tube placed in the coronary arteries to keep them open. The study will compare the effects of a standard dual antiplatelet therapy (using two medications) with an abbreviated, or shortened, therapy. Participants will be randomly assigned to receive either the standard or the abbreviated therapy. The study will last for up to 12 months, during which the rate of heart-related complications and bleeding events will be monitored.

Participants will take the medications orally, meaning they will swallow them in pill form. The study aims to determine if the abbreviated therapy is as effective as the standard therapy in preventing heart-related issues while also reducing the risk of bleeding. This research is important for understanding how to best manage treatment for patients with coronary artery disease who have received a stent.

Participants in the study will receive an injection of SYN2 and undergo a PET scan. This scan will help doctors determine if there are any significant blockages in the heart’s blood vessels. The study will also involve the use of other medications, such as Adenosine and Regadenoson, which are used to help stress the heart during the imaging process. These medications are given through an infusion, which is a way of delivering medicine directly into the bloodstream.

The study will take place over a short period, with participants attending a few visits to complete the necessary tests and scans. The results from the SYN2 PET scan will be compared to the results from other standard tests to evaluate its effectiveness in diagnosing CAD. Participants will be monitored for any side effects or changes in their health during the study. The goal is to improve the way CAD is diagnosed, potentially leading to better treatment options for patients in the future.

Participants in the study will receive one of the treatments and will be monitored over time to see how well the treatment works and to check for any side effects. The medications involved in the study include Aspirin Cardio, which contains acetylsalicylic acid, Plavix, which contains clopidogrel, Efient, which contains prasugrel, and Brilique, which contains ticagrelor. These medications are commonly used to prevent blood clots in patients with heart conditions.

The study will last for several years, with participants being followed up at different intervals to assess their health and the effectiveness of the treatment. The main focus will be on the occurrence of major heart-related events and bleeding episodes. This research aims to find the best treatment strategy for patients with coronary artery disease who are at high risk of bleeding, ensuring they receive effective care with minimal side effects.

The purpose of the study is to understand how well SYN2 can measure blood flow in the heart compared to the traditional method. Participants will receive injections of SYN2 and undergo imaging tests to see how the blood flows through their heart. Some participants may also receive a different medication called Rapiscan or Adenosine, which are also solutions for injection, to help with the imaging process. A placebo may be used in some cases to compare the effects of the treatments.

The study will involve several visits where participants will receive the injections and have imaging tests done. The goal is to see if SYN2 provides accurate and reliable measurements of heart blood flow, which could help improve the diagnosis and treatment of Coronary Artery Disease in the future. Participants will be monitored closely throughout the study to ensure their safety and well-being.

The purpose of the study is to confirm how well O15-Water can help identify CAD when the heart is at rest and during stress, which is when the heart is working harder than usual. Participants will receive the O15-Water infusion and undergo PET imaging. The results will be compared to other standard tests that look at the heart’s blood vessels, such as an Invasive Coronary Angiogram (ICA) or a Coronary Computed Tomography Angiogram (CCTA).

The study will take place over a period of time, and participants will be monitored to see how well the O15-Water works in detecting significant CAD. The goal is to determine the accuracy of this method in identifying heart disease, which could help improve diagnosis and treatment for patients with CAD in the future.

The purpose of the study is to determine if using a personalized approach to choosing these medications, based on a person’s genetic makeup, can improve the effectiveness of the treatment. This involves using a genetic test to guide the selection of the most suitable anti-platelet drug for each patient. The study will compare this personalized approach to the standard treatment, which typically involves using a combination of two anti-platelet drugs. The main focus will be on how well the medications prevent platelets from clumping together, which is measured using a test called the VerifyNow system.

Participants in the study will be randomly assigned to either the personalized treatment group or the standard treatment group. The study will last for about six months, during which time the effectiveness and safety of the treatments will be monitored. This includes checking for any bleeding complications and other heart-related events. The goal is to find out if the personalized approach can provide better protection against blood clots while minimizing the risk of bleeding.

The purpose of the study is to assess both the risk of heart-related problems and the risk of bleeding when using Clopidogrel in this way. Participants will be monitored for six months after their PCI procedure. During this time, researchers will look at the occurrence of events such as heart attacks, strokes, and any bleeding issues. The study will also compare these outcomes to those of patients who might receive other treatments, including a placebo.

Throughout the study, participants will take Clopidogrel in the form of film-coated tablets. Another medication, Acetylsalicylic Acid, commonly known as aspirin, may also be used in some cases. The study aims to provide valuable information on the safety and effectiveness of Clopidogrel for patients with these heart conditions, helping to guide future treatment decisions.

Participants in the study will be randomly assigned to receive either the dual therapy of ticagrelor and aspirin or aspirin alone. The study will monitor the participants over a period of 12 months to observe the occurrence of major adverse cardiovascular events, which include serious issues like heart attacks, strokes, or the need for additional heart procedures. The study aims to see if the combination of medications can reduce these events compared to using aspirin alone.

The trial will help to understand whether adding ticagrelor to the standard aspirin treatment can provide better protection against heart-related complications after surgery. This research is important for improving treatment strategies for patients with acute coronary syndrome who have undergone CABG, potentially leading to better long-term health outcomes.